Wij zijn onze website aan het vernieuwen.

Ontdekt u nog een pagina die niet klopt of hebt u een goede suggestie, laat het ons dan weten via webmedia@umcutrecht.nl.

Deze website maakt gebruik van cookies

Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Lees meer over het cookiebeleid.

prof. dr. S.C. Linn Full Professor

  • Department of Pathology

Contact

Research Programs

Side Activities

  • For information about current outside activities please see www.nki.nl

Research Output (96)

POSEIDON trial phase 1B results:Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients

Baird Richard D., van Rossum Annelot G.J., Oliveira Mafalda, Beelen Karin, Gao Meiling, Schrier Mariette, Mandjes Ingrid A.M., Garcia-Corbacho Javier, Vallier Anne Laure, Dougall Greig, van Werkhoven Erik, Linossi Constanza, Kumar Sanjeev, van Tinteren Harm, Callari Maurizio, Beddowes Emma, Perez-Garcia Jose Manuel, Rosing Hilde, Platte Else, Nederlof Petra, Schot Margaret, de Vries Schultink Aurelia, Bernards Rene, Saura Cristina, Gallagher William, Cortes Javier, Caldas Carlos, Linn Sabine C. 15 nov 2019, In: Clinical Cancer Research. 25 , p. 6598-6605 8 p.

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer

Severson Tesa M., Kim Yongsoo, Joosten Stacey E.P., Schuurman Karianne, Van Der Groep Petra, Moelans Cathy B., Ter Hoeve Natalie D., Manson Quirine F., Martens John W., Van Deurzen Carolien H.M., Barbe Ellis, Hedenfalk Ingrid, Bult Peter, Smit Vincent T.H.B.M., Linn Sabine C., Van Diest Paul J., Wessels Lodewyk, Zwart Wilbert 1 dec 2018, In: Nature Communications. 9

FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome

Schrijver Willemijne, Schuurman Karianne, van Rossum Annelot, Droog Marjolein, Jeronimo Carmen, Salta Sofia, Henrique Rui, Wesseling Jelle, Moelans Cathy, Linn Sabine C, van den Heuvel Michel, van Diest Paul, Zwart Wilbert 1 nov 2018, In: Molecular Oncology. 12 , p. 1884-1894 11 p.

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

Beelen Karin, Opdam Mark, Severson Tesa, Koornstra Rutger, Vincent Andrew, Wesseling Jelle, Sanders Joyce, Vermorken Jan, van Diest Paul, Linn Sabine 24 jul 2018, In: BMC Cancer. 18

Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis:A population-based cohort study

Dackus G. M.H.E., Jóźwiak Katarzyna, Sonke Gabe S, van der Wall E., van Diest P. J., Hauptmann M., Siesling S., Linn S. C. 21 dec 2017, In: European Journal of Cancer. 90 , p. 92-101 10 p.

BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial

van Rossum A. G.J., Schouten Philip C, Weber K. E., Nekljudova V., Denkert Carsten, Solbach C., Köhne C. H., Thomssen C., Forstbauer H., Hoffmann G., Kohls A., Schmatloch S., Schem C., von Minckwitz G., Karn T., Möbus V. J., Linn S. C., Loibl S., Frederik Marmé Marmé dec 2017, In: Breast Cancer Research and Treatment. 166 , p. 775-785 11 p.

Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment:protocol for the PARADIGM initiative cohort study

Dackus Gwen Mhe, Ter Hoeve Natalie D., Opdam Mark, Vreuls Willem, Varga Zsuzsanna, Koop Esther, Willems Stefan M., Van Deurzen Carolien Hm, Groen Emilie J., Cordoba Alicia, Bart Jos, Mooyaart Antien L., van den Tweel Jan G., Zolota Vicky, Wesseling Jelle, Sapino Anna, Chmielik Ewa, Ryska Ales, Amant Frederic, Broeks Annegien, Kerkhoven Ron, Stathonikos Nikolas, Veta Mitko, Voogd Adri, Jozwiak Katarzyna, Hauptmann Michael, Hoogstraat Marlous, Schmidt Marjanka K., Sonke Gabe, van der Wall Elsken, Siesling Sabine, van Diest Paul J., Linn Sabine C. 14 nov 2017, In: BMJ open [E]. 7

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA):a randomised, phase 3 trial

Tjan-Heijnen Vivianne C G, van Hellemond Irene E G, Peer Petronella G M, Swinkels Astrid C P, Smorenburg Carolien H, van der Sangen Maurice J C, Kroep Judith R, De Graaf Hiltje, Honkoop Aafke H, Erdkamp Frans L G, van den Berkmortel Franchette W P J, de Boer Maaike, de Roos Wilfred K, Linn Sabine C, Imholz Alexander L T, Seynaeve Caroline M, nov 2017, In: LANCET ONCOLOGY. 18 , p. 1502-1511 10 p.

Stimulation of the ovaries in women with breast cancer undergoing fertility preservation:Alternative versus standard stimulation protocols; the study protocol of the STIM-trial

Dahhan T., Balkenende E.M., Beerendonk C. C.M., Fleischer K., Stoop D., Bos A. M.E., Lambalk Cornelis B., Schats R, van Golde Ron J T, Schipper I., Louwé L. A., Cantineau A. E.P., Smeenk Jesper M J, Bruin Jacob P, Reddy D N, Kopeika Y., van der Veen F, Wely M., Linn S. C., Goddijn M. 1 okt 2017, In: Contemporary Clinical Trials. 61 , p. 96-100 5 p.

The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

Severson Tesa M, Wolf Denise M., Yau Christina, Peeters Justine K, Wehkam Diederik, Schouten Philip C, Chin Suet-Feung, Majewski Ian J, Michaut Magali, Bosma Astrid J, Pereira Bernard, Bismeijer Tycho, Wessels Lodewyk F A, Caldas Carlos, Bernards René, Simon Iris M, Glas Annuska M., Linn Sabine, Van't Veer Laura J. 25 aug 2017, In: Breast Cancer Research. 19

All Research Output (96)
To top